Repros hires Donald Tredway as CMO
This article was originally published in Scrip
Focused on developing oral small molecule drugs for reproductive disorders, Repros Therapeutics has appointed Dr Donald Tredway chief medical officer. Dr Tredway was vice-president and global head of the fertility and endocrinology GCDU for EMD Serono until July 2009, when he retired. He has subsequently been acting as a regulatory and clinical development consultant to several pharmaceutical companies.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.